UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1926, 2026

MEREO BIOPHARMA GROUP PLC

(Exact name of registrant as specified in its charter)



England and Wales	001-38452	Not Applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4th Floor, One Cavendish Place,

London, W1G 0QF

United Kingdom

(Address of principal executive offices, including zip code)

+44-333-023-7300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share	MREO	The Nasdaq Stock Market LLC
Ordinary Shares, nominal value £0.003 per share*	*	The Nasdaq Stock Market LLC

*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02 ~~Results~~- Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 1926, 2026, Dr. Annalisa Jenkins informed Mereo BioPharma ~~Group~~ plc. ~~announced~~(the ~~its~~“Company”) ~~financial~~that ~~results~~she will not stand for re-election as a Director of the ~~year~~Board ~~ended~~of ~~December~~Directors 31(the “Board”) of the Company at the Company’s 2026 annual general meeting of shareholders (the “2026 AGM”), ~~2025~~scheduled ~~and~~for ~~provided~~May ~~recent~~14, ~~corporate~~2026. ~~highlights~~Dr. ~~The~~Jenkins ~~full~~will ~~text~~continue to serve out the remainder of her term, which will expire immediately prior to the ~~press~~2026 ~~release~~AGM. ~~issued~~Dr. inJenkins’ ~~connection~~decision not to stand for re-election did not result from any disagreement with the ~~announcement~~Company isor ~~furnished~~the asBoard ~~Exhibit~~on ~~99.1~~any matter relating to ~~this~~the ~~Current~~Company’s ~~Report~~operations, onpolicies ~~Form~~or ~~8-K~~practices.

The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description of Exhibit
99.1	Press Release, dated March 19, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	MEREO BIOPHARMA GROUP PLC
Date: March 19, 2026	By:	/s/ Christine Fox
Date: March 27, 2026	By:	/s/ Charles Sermon
		Name:	~~Christine~~Charles ~~Fox~~Sermon
		Title:	~~Chief~~General ~~Financial Officer~~Counsel

Filing Compare · Mereo BioPharma Group plc